Targovax ASA (GB:0RIS) has released an update.
Circio Holding ASA successfully conducted its annual general meeting, approving all board resolutions, including the 2023 annual accounts and a rights issue to raise approximately NOK 52 million. Additionally, the company is advancing its proprietary circular RNA platform, circVec, and its cancer vaccine, TG01, which is in clinical trials for various cancers. The rights issue, aiming to raise further capital, will be available for subscription from 24 June 2024 to 8 July 2024.
For further insights into GB:0RIS stock, check out TipRanks’ Stock Analysis page.
